Table 1.
Descriptive statistics of the development and validation cohorts.
| Development cohort | Validation cohort | |
|---|---|---|
| Demographics | ||
| Patient, N | 165 | 101 |
| Total daily measurements, N | 92,787 | 40,185 |
| Observational period, median (25–75) | 610 (580–640) | 417 (376–473) |
| Age, median (25–75) | 38 (28–47) | 46.5 (34–56) |
| Sex (female), N (%) | 92 (56%) | 62 (61%) |
| Predictors | ||
| Peak expiratory flow, mean (std) | 438 (98) | 404 (104) |
| Missing (%) | 477 (0.5%) | 1171 (2.9%) |
| Peak expiratory flow personal besta, mean (std) | 467 (100) | 437 (103) |
| Nocturnal awakening, mean % per patient | 6.3% | 4.7% |
| Missing (%) | 876 (0.9%) | 1665 (4.1%) |
| Use of 2 reliever, mean % per patient | 7.2% | 8.9% |
| Missing (%) | 302 (0.3%) | 1188 (3.0%) |
| Outcome | ||
| Exacerbations per patient, N (%) | ||
| 0 exacerbations | 116 (70%) | 63 (62%) |
| 1 exacerbation | 25 (15%) | 20 (20%) |
| 2 or more exacerbations | 24 (15%) | 18 (18%) |
| Total exacerbations, N (%) | 154 (0.2%) | 94 (0.2%) |
Statistics were calculated for each individual patient over their respective observational periods. Then these statistics were pooled across patients.
aNo % missing is reported for maximum peak expiratory flow as this is a summary statistic calculated per patient over a run-in period of 4 weeks.